Using a combination of in vitro intracellular VP accumulation assays, P-gp substrate retention experiments, and Seahorse-based metabolic profiling, we identified NanoVP as the lead formulation for P-gp modulation in cancer cells. The gene discussed is PGP; the disease is cancer.